Table 1 Details of reported clinical studies of different drug use in the treatment of ischemia
From: Cerebral ischemic stroke and different approaches for treatment of stroke
Name of drug | Mechanism of action as neuroprotection | Remark |
|---|---|---|
Selfotel | Competitive glutamate receptor antagonist | Phase III trial stopped because of adverse effects |
Eliprodil | Glutamate antagonist at polyamine modulator site | Phase III trial ceased due to no efficacy |
Aptiganel | Noncompetitive NMDA channel blocker | Ineffective for acute stroke therapy in phase III trial |
LeukArrest | Anti-inflammatory monoclonal antibodies | Phase III trial stopped because of unfavorable results |
Fosphenytoin | Sodium channel blocker and blocks calcium ions entry also | Phase III trial stopped due to non-beneficial results |
Maxipost | Potassium channel activator | Phase III trial results fail |
Citicoline | Membrane stabilization and improvement in infarct size | Ineffective in phase III trial |
Clomethiazole | Gamma-amino butyric acid receptor antagonist | Phase III trial aborted due to response failure from the patient |
Repinotan | Serotonin agonist | Phase II trial shows neuroprotective effect |